Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...
EP Lab
This channel includes news and new technology innovations for cardiac electrophysiology (EP) systems, techniques and devices using in EP labs. This includes implantable EP devices, pacemakers, implantable cardioverter defibrillators (ICD), cardiac resychronization therapy (CRT), ablation technologies, left atrial appendage (LAA) occlusion, atrial fibrilation (AF) and Holter monitors.
Dec. 19, 2025 — Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by ...
December 19, 2025
Dec. 3, 2025 — Recross Cardio Inc., a structural heart company developing next-generation membrane sealing technology ...
December 04, 2025Sponsored Content
Feature | ECG
When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “The newer ECG devices we have now are so much less cumbersome. It’s like wearing a Band-Aid versus carrying a bulky device,” said the Greenwood, Mississippi internist. “My patients prefer the more comfortable, wire-free form factor, and the quality is as good as, or better, than the Holter,” continued Boler. “Plus, my patient compliance has increased. With the Holter, the leads sometimes come off. The patient may think the device isn’t working, so they take it off and we have to restart the process.”
February 19, 2020
Nov. 10, 2025 — Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its latest generation ...
November 11, 2025
Oct. 22, 2025 -- Medical robotics innovator Noah Medical presented two new data sets highlighting the clinical and ...
November 03, 2025
Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...
October 13, 2025Sponsored Content
Feature | Sudden Cardiac Arrest
Sudden cardiac death (SCD) is the leading medical cause of death in young athletes and its impact is consistent worldwide. Most professional athletes in the United States are required to take part in comprehensive cardiovascular screening programs to identify often-asymptomatic congenital or inherited heart disorders, and other cardiac risk factors. There remains a debate however, whether to mandate ECGs as part of pre-participation screening programs for student athletes at the collegiate and high school levels or even at younger ages.
October 16, 2018
Oct. 10, 2025 — Berlin Heals Holding AG, a clinical-stage medical device company focused on revolutionizing the care of ...
October 13, 2025
Feature | Renal Denervation | Kyle Hardner
Hypertension remains the leading modifiable driver of cardiovascular disease and premature death.1 Even with multiple ...
October 02, 2025
Sept. 29, 2025 — Radiation therapy may offer a comparable and potentially safer alternative to repeat catheter ablation ...
September 30, 2025Sponsored Content
Feature | Atrial Fibrillation
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time ...
September 13, 2018
Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...
September 23, 2025
Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) reve ...
September 22, 2025
Sept. 16, 2025 — Elutia Inc., a pioneer in drug-eluting biomatrix technologies, has published clinical and preclinical ...
September 19, 2025Sponsored Content
Blog | Remote Monitoring
There is a movement toward real-time, remote cardiac monitoring with the latest generation of event and Holter monitor ...
June 20, 2018
Feature | Atrial Fibrillation | Jeffrey Olgin, M.D.
Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable ...
September 12, 2025
Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...
September 08, 2025
Sept. 8, 2025 — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic ...
September 08, 2025